CHOP overexpression sensitizes human non-small cell lung cancer cells to cisplatin treatment by Bcl-2/JNK pathway. 2021

Li-Le Wang, and Rui-Cheng Hu, and Ai-Guo Dai, and Shuang-Xiang Tan, and Ming Xu, and Chun-Chu Kong, and Yun-Rong Chen, and Dai-Yan Fu
Department of Respiratory Medicine, Hunan Provincial People's Hospital/The First Affiliated Hospital of Hunan Normal University Changsha 410016, China.

C/EBP homologous protein (CHOP), a 29 kDa cellular protein, plays a role in regulating tumor proliferation, differentiation, metabolism, cell death, and in tumor resistance to chemotherapy. Non-small cell lung cancer (NSCLC) is a tumor of the respiratory system and drug resistance is prevalent among NSCLC clinical cell cultures. Herein, our study elucidated the effect of CHOP on NSCLC cells with cisplatin resistance and its mechanism. In a NSCLC cell line with cisplatin-resistance, CHOP expression was decreased, compared with A549 cells. Overexpression of CHOP decreased the cell viability and enhanced cell apoptosis in the cells treated with cisplatin. Expression of CHOP also inhibited the cell proliferation and metastasis. CHOP increased the therapeutic effect of cisplatin on NSCLC cells through the Bcl-2/JNK pathway. In summary, CHOP regulated cisplatin resistance in cells of NSCLC by promoting the expression of apoptotic proteins and inhibiting the Bcl-2/JNK signaling pathway, indicating the antitumor effects of CHOP.

UI MeSH Term Description Entries

Related Publications

Li-Le Wang, and Rui-Cheng Hu, and Ai-Guo Dai, and Shuang-Xiang Tan, and Ming Xu, and Chun-Chu Kong, and Yun-Rong Chen, and Dai-Yan Fu
May 2008, International journal of cancer,
Li-Le Wang, and Rui-Cheng Hu, and Ai-Guo Dai, and Shuang-Xiang Tan, and Ming Xu, and Chun-Chu Kong, and Yun-Rong Chen, and Dai-Yan Fu
August 2010, PloS one,
Li-Le Wang, and Rui-Cheng Hu, and Ai-Guo Dai, and Shuang-Xiang Tan, and Ming Xu, and Chun-Chu Kong, and Yun-Rong Chen, and Dai-Yan Fu
October 2019, Molecular medicine reports,
Li-Le Wang, and Rui-Cheng Hu, and Ai-Guo Dai, and Shuang-Xiang Tan, and Ming Xu, and Chun-Chu Kong, and Yun-Rong Chen, and Dai-Yan Fu
August 2007, Anti-cancer drugs,
Li-Le Wang, and Rui-Cheng Hu, and Ai-Guo Dai, and Shuang-Xiang Tan, and Ming Xu, and Chun-Chu Kong, and Yun-Rong Chen, and Dai-Yan Fu
September 2017, Journal of experimental & clinical cancer research : CR,
Li-Le Wang, and Rui-Cheng Hu, and Ai-Guo Dai, and Shuang-Xiang Tan, and Ming Xu, and Chun-Chu Kong, and Yun-Rong Chen, and Dai-Yan Fu
May 2007, Acta biochimica et biophysica Sinica,
Li-Le Wang, and Rui-Cheng Hu, and Ai-Guo Dai, and Shuang-Xiang Tan, and Ming Xu, and Chun-Chu Kong, and Yun-Rong Chen, and Dai-Yan Fu
November 2007, Acta biochimica et biophysica Sinica,
Li-Le Wang, and Rui-Cheng Hu, and Ai-Guo Dai, and Shuang-Xiang Tan, and Ming Xu, and Chun-Chu Kong, and Yun-Rong Chen, and Dai-Yan Fu
September 2013, International journal of molecular medicine,
Li-Le Wang, and Rui-Cheng Hu, and Ai-Guo Dai, and Shuang-Xiang Tan, and Ming Xu, and Chun-Chu Kong, and Yun-Rong Chen, and Dai-Yan Fu
January 2015, Neoplasma,
Li-Le Wang, and Rui-Cheng Hu, and Ai-Guo Dai, and Shuang-Xiang Tan, and Ming Xu, and Chun-Chu Kong, and Yun-Rong Chen, and Dai-Yan Fu
January 2015, PloS one,
Copied contents to your clipboard!